Mecapegfilgrastim to help collect stem cells for transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 study tests mecapegfilgrastim with chemotherapy to help your body collect enough peripheral blood stem cells for an autologous transplant (using your own cells). It’s for people with multiple myeloma or certain lymphomas who have already had some response to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma (one prior treatment line) or lymphoma (two or fewer prior treatment lines)
- Your disease has at least partially responded to past treatment
- You are eligible to get an autologous stem cell transplant using your own stem cells
- You are age 18–65, and your daily function is good (ECOG 0–1)
- You have enough time to live with benefit (more than 3 months) and can sign written consent
- If you can become pregnant, you must use reliable birth control during the study and for 90 days after the last dose, with a negative pregnancy test before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different combinations of medicines to help collect stem cells for a transplant in people newly diagnosed with multiple myeloma. The goal is to see which approach works better and is safer for you.
This Phase 1 study tests a carfilzomib-based treatment plan to help people with multiple myeloma collect enough stem cells for an autologous (using your own) stem cell transplant. It’s mainly about whether this mobilization approach works and is safe for you.
This trial tests a new drug, motixafortide, combined with a standard growth factor (G-CSF) to help collect stem cells for a transplant in people with multiple myeloma. It may be a good option if your myeloma is in remission and you have not had a stem cell transplant before.
This study tests if adding Mozobil (a drug that helps release stem cells) before stem cell transplant can improve outcomes for people with multiple myeloma, Hodgkin's lymphoma, or non-Hodgkin lymphoma. If you are eligible, you will receive Mozobil along with standard stem cell mobilization medicines.
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
This trial studies how safe eflapegrastim is in pediatric patients with certain solid tumors or lymphomas who are starting chemotherapy that lowers white blood cells. It also looks at how the medicine behaves in the body to help reduce the risk of dangerous infections.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.